Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
eltrombopag (Revolade®)
Reference No. 607
Publication date:
25/07/2014
Appraisal information
eltrombopag (Revolade®) 25 mg film-coated tablet
eltrombopag (Revolade®) 50 mg film-coated tablet
Company:
Novartis Pharmaceuticals UK Ltd
BNF category:
Nutrition and blood
NMG meeting date:
14/05/2014
AWMSG meeting date:
11/06/2014
Submission Type:
Full Submission
Status:
Recommended
Advice No:
1314
Ministerial ratification:
24/07/2014
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification
AWMSG advice
Eltrombopag (Revolade®) is recommended for use within NHS Wales in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon based therapy. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
eltrombopag (Revolade) 607 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
eltrombopag (Revolade) 607 ASAR
Clinical Expert (CE) Summary
Download
eltrombopag (Revolade) 607 CE summary
